Form 4: Senti Biosciences Director Donald F. Tang Granted Stock Options

Senti Biosciences, Inc. Director Donald F. Tang was granted 21,950 stock options with an exercise price of $2.05, aligning his interests with shareholder value.

Summary

• Donald F. Tang, a Director of Senti Biosciences, Inc. (SNTI), was granted 21,950 stock options.
• The options have an exercise price of $2.05 per share.
• The transaction date for this grant was June 25, 2025.
• The options are set to expire on June 24, 2035.
• 100% of the shares underlying these options will vest upon the earlier of the first anniversary of the grant date or the date of the 2026 Annual Meeting, contingent on Mr. Tang's continued service.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally viewed as a positive signal, as it aligns the director's financial interests with the long-term performance of the company and shareholder value, indicating confidence and commitment.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company and shareholder value.
• It indicates continued commitment and incentivization for the director's service to the company.

Risks

• Potential future dilution for existing shareholders if the stock options are exercised, increasing the number of outstanding shares.
• The value of the options is dependent on the future market price of Senti Biosciences' common stock, which is subject to market volatility and company performance.

Future Outlook

The vesting schedule of the granted stock options indicates an expectation of Donald F. Tang's continued service as a director through at least the first anniversary of the grant date or the 2026 Annual Meeting, whichever comes first.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages designed to attract, retain, and incentivize leadership by aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• NA This filing does not provide sufficient detail to compare the specific compensation structure (e.g., total compensation, equity mix, performance hurdles) to broader industry benchmarks or specific comparable companies within the biotechnology sector.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Donald F. Tang constitutes a related party transaction, as it involves compensation provided by Senti Biosciences, Inc. to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for increased alignment of director interests with shareholder value; potential future dilution if options are exercised, increasing the number of outstanding shares.
• Employees: No direct impact mentioned, but reflects the company's compensation philosophy for key personnel.

Next Steps

• The stock options will vest upon the earlier of the first anniversary of the grant date (June 25, 2026) or the 2026 Annual Meeting, subject to continued service.
• Following vesting, Donald F. Tang will have the right to exercise these options to purchase common stock at the specified exercise price until the expiration date.

Key Dates

Keywords

Senti Biosciences, SNTI, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation